Stanford scientists have identified tuberculosis (TB) epitopes preferentially recognized by T cells in patients who naturally resist or control TB infection. Targeting these epitopes for vaccine development could lead to effective vaccines for TB.
Stanford researchers have created a new strategy for collecting and integrating human microbiome, multi-omics, and immune cell activation data that reveals new insights into the roles of different bacterial strains in human health.
Stanford researchers have identified that increased oxidative stress is a key molecular signature of fatigue-based conditions including Long COVID and myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS).
The recognition of peptide-MHC (pMHC) complexes by T cells is the cornerstone of cellular immunity, enabling the elimination of infected or tumoral cells. pMHC can thus be leveraged as a detection tool for T cells.
Stanford scientists designed a nanobody platform to inhibit the activity of granulysin, a protein that is often found in arterial plaque and released by T cells, to prevent the development of atherosclerosis such as heart attack and strokes.
Researchers at Stanford have discovered that nanobodies blocking amphiregulin (AREG) activity have the potential to impede the progression of early-stage atherosclerotic plaque lesions to advanced-stage fibroatheromas.
Stanford researchers have designed a nanobody platform to selectively block a key region on T cells found within arterial plaque, with the aim of preventing thrombotic complications and myocarditis.
Stanford scientists have discovered that cross-linking antigens can overcome sub-type bias in response to multi-strain vaccines and induce patients to have a complete, broad immune response to all included antigens.
Researchers at Stanford have developed a nanoparticle-based platform to enhance activation of self-specific CD8+ T cells in the tumor microenvironment to fight cancer while minimizing toxic side effects.
Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity.
Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.
Stanford researchers in the Mark Davis Lab have developed a human cell culture system to grow 3D immune organoids within hydrogel structures using limited cellular input that can be adapted to large screening assays for flexible downstream immunological readouts.
Scientists from the Davis and Mackall labs at Stanford have discovered T cell receptor molecules targeting a novel antigen upregulated in cancer. This discovery has potential value for cancer-targeting therapies, particularly CAR T therapies.
Scientists from the Davis and Mackall labs at Stanford have discovered T cell receptor molecules targeting a novel antigen upregulated in cancer. This discovery has potential value for cancer-targeting therapies, particularly CAR T therapies.
A team of Stanford researchers have identified a set of biomarkers that could be used to recognize patients with age-related declines in their immune function.